Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …

Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the
aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes …

Background Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …

Purpose To test the hypothesis that thrombus-specific tissue plasminogen activator (tPA)-
loaded nanocarriers enhance thrombolytic efficacy and attenuate hemorrhagic …

Essentials• Vessel stenosis due to large thrombus formation increases local shear 1‐2
orders of magnitude.• High shear at stenotic sites was exploited to trigger eptifibatide …

For the purpose of efficient hemostasis, we previously developed ADP-encapsulated
liposomes modified with a dodecapeptide (HHLGGAKQAGDV, H12), H12-(ADP) Lipo. This …

Fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)–coated, ADP-encapsulated
liposomes [H12-(ADP)-liposomes] were developed as a synthetic platelet alternative that …

Local drug delivery has become an important treatment modality for the prevention of
thrombotic events following coronary angioplasty. In this study, we investigate the ability of …

ABSTRACT A fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated,
adenosine diphosphate (ADP)-encapsulated liposome [H12-(ADP)-liposome] was designed …

Rutin (RUT) is a flavonoid obtained from a natural source and is reported for antithrombotic
potential, but its delivery remains challenging because of its poor solubility and …